Clinical trials: Vomit
Chemotherapy-Induced Nausea and Vomiting
A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00971633
- Testing
- Comparator: Treatment A (Zofran, ondansetron), Comparator: Treatment B (Zofran, ondansetron), Comparator: Treatment C (Zofran, ondansetron)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
This is an open-label, randomized, single-dose, single-center, parallel-group bioequivalence study of orally- and IV-administered rolapitant in healthy male and female subjects.
- Trial name
- NCT02285647
- Testing
- Rolapitant - Oral, Rolapitant - IV
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Vomiting, Cardiovascular Event
CV Events in Emetogenic Chemotherapy
Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
- Conditions
- Vomiting, Cardiovascular Event, Arterial Thromboembolic Event
- Trial name
- NCT01366599
- Testing
- HEC or MEC
- Volunteers
- 12,058 people
- Sponsor
- GlaxoSmithKline
Postoperative Nausea and Vomiting
Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)
The purpose of this study is to investigate palonosetron versus ondansetron as rescue medication in subjects that develop postoperative nausea and vomiting (PONV) in the Postanaesthesia Care Unit (PACU).
- Trial name
- NCT00967499
- Testing
- Ondansetron, Palonosetron
- Where
- 8 sites in United States
- Volunteers
- 239 people
- Sponsor
- Eisai Inc.
Post-operative Nausea and Vomiting
Mass-balance Study of [14C]-APD421 in Healthy Volunteers
Open-label, non-randomised, single dose study in 6 healthy male subjects to assess the mass balance recovery, metabolite profile, metabolite identification and pharmacokinetics of 14C-labelled APD421
- Trial name
- NCT02881840
- Testing
- 14C-APD421
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Post-Operative Nausea and Vomiting (PONV)
Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)
The purpose of this study is to describe the safety and tolerability and pharmacokinetics of a single intravenous administration of the new, Sulfobutyl Ether-7-Beta-Cyclodextrin (Captisol™) based, formulation in Healthy Adult…
- Trial name
- NCT01290133
- Testing
- GW597599
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Accenture
Nausea and Vomiting, Chemotherapy-Induced
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
This is a two period study of healthy adult subjects to characterize the effect of the dosing of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the safety profile of oral casopitant with and…
- Trial name
- NCT00404378
- Testing
- ketoconazole, casopitant 100 mg, Casopitant 50 mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
The purpose of this study is to examine the pharmacokinetics (PK), safety and tolerability of 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS) as compared to Granisetron IV Injection…
- Trial name
- NCT02563951
- Testing
- GNS Spray 0.5mg, GNS Spray 1.0mg, GNS Spray 2.0mg
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Maxinase Life Sciences Ltd.
Vomiting
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants.
- Trial name
- NCT00080444
- Testing
- aprepitant, ondansetron, dexamethasone
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
- Trial name
- NCT03383146
- Testing
- Relamorelin
- Where
- 349 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Allergan
Postoperative Nausea and Vomiting
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
This study will evaluate single IV doses of Vestipitant (GW597599) compared to 4 mg IV ondansetron for treating breakthrough postoperative nausea and vomiting (PONV) after failure of PONV prophylaxis with a regimen that includes…
- Trial name
- NCT01507194
- Testing
- Ondansetron, Vestipitant
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- Accenture
Motion Sickness
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion
- Trial name
- NCT04947423
- Testing
- DPI-386 Nasal Gel
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd
Chemotherapy-induced Nausea and Vomiting
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple…
- Trial name
- NCT02434861
- Testing
- Rolapitant, Digoxin, Sulfasalazine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Chemotherapy-Induced Nausea and Vomiting (CINV)
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.
- Trial name
- EASE (NCT00619359)
- Testing
- Comparator: fosaprepitant dimeglumine, Comparator: Aprepitant, Dexamethasone
- Volunteers
- 2,322 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomiting, Postoperative
Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients
Randomized, double-blind, pediatric trial of amisulpride for prophylaxis of post operative nausea and vomiting
- Trial name
- NCT05546359
- Testing
- Amisulpride Injection, Dexamethasone
- Where
- 14 sites in United States, Canada and 2 more
- Volunteers
- 453 people
- Sponsor
- Acacia Pharma Ltd
Gastroenteritis
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
The purpose of this study is to give children with gastroenteritis with persistent vomiting flavored intravenous ondansetron orally.
- Trial name
- NCT02473887
- Testing
- Ondansetron with1:1 ORA - sweet.
- Volunteers
- 40 people
- Sponsor
- Hamad Medical Corporation
Prevention of Postoperative Nausea and Vomiting
A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting
The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for…
- Trial name
- NCT07709897
- Testing
- HRS5580 for injection combined with palonosetron hydrochloride;, HRS5580 for injection combined with palonosetron hydrochloride, HRS5580 for injection blank preparation combined with palonosetron hydrochloride
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.